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Ab s t r Ac t
Liver carcinosarcoma is a rare entity, with only 42 cases reported so far. World Health Organization (WHO) has defined carcinosarcoma as a 
mixture of both carcinomatous and sarcomatous components. They have an aggressive behaviour with poor outcome. Unlike hepatocellular 
carcinoma, there is no characteristic imaging feature to diagnose hepatic carcinosarcomas. Surgery remains the only curative option. There 
is no established optimal chemotherapy regimen for carcinosarcoma. Here we present two cases of primary hepatic carcinosarcoma with 
extensive metastases. 
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In t r o d u c t I o n
Liver carcinosarcomas were first described by Craig et al. in 1989. He 
defined carcinosarcoma of the liver as a mixture of hepatocellular 
carcinoma (HCC) and non-spindle cell sarcoma components with 
specialized differentiation into malignant muscle, cartilage or bone 
component. WHO defines human chorionic somatomammotropic 
(HCS) as a mixture of carcinomatous components, either HCC or 
comprehensive care center (CCC) and sarcomatous components.
Hepatic carcinosarcoma is a rare malignancy with only 42 case 
reports so far. HCS is more common in men than women with an 
incidence ratio of 3:1. 50% were positive for Hepatitis B and 40% 
exhibited elevated AFP levels.[1] Nearly 70% of patients with HCS 
had advanced disease at presentation. The most common sites of 
metastases were lung and lymph nodes. 
We present two case reports of metastatic hepatic carcino-
sarcoma.
cA s e re p o r t-1 
A 66-year-old male patient, known diabetic and hypertensive, 
presented with the complaints of low backache for a month and 
was evaluated. Blood investigations showed hypoalbuminemia and 
leukocytosis. Ultrasound abdomen showed multiple hypoechoic 
nodular lesions in the liver. Magnetic resonance imaging (MRI) 
spine was suggestive of multiple bone secondaries. He was 
further evaluated with Positron emission tomography–computed 
tomography (PET-CT) whole body, which showed an intrahepatic 
mass probably cholangiocarcinoma with liver and bone secondaries. 
CA19-9 was mildly elevated at 55.8U/mL. Biopsy and IHC from the 
liver mass were consistent with Carcinosarcoma (Pancytokeratin 
AE1 + AE3 – positive, CK7 positive, vimentin positive, FL-1 positive, 
Figure 1 and 2: Positron emission tomography–computed tomography suggestive of intrahepatic mass probably cholangiocarcinoma with 
liver and bone secondaries.
SMA positive). He was started on palliative chemotherapy with 
gemcitabine and cisplatin (Figures 1 and 2). 
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cA s e re p o r t 2
A 57-year-old male had presented with complaints of loss of 
weight and appetite for a month and was evaluated. Blood 
investigations showed direct hyperbilirubinemia. Ultrasonography 
(USG) abdomen showed multiple hypoechoic liver lesions with 
IHBR dilatation and splenomegaly. CT abdomen showed multiple 
hypodense lesions in both lobes of liver with IBR dilatation and 
diffuse GB wall thickening. PET CT raised the possibility of hilar 
cholangiocarcinoma with hepatic adrenal and skeletal mets. 
Carcinoembryonic antigen (CEA) was elevated at 22.6 ng/mL. Biopsy 
and IHC was suggestive of carcinosarcoma (Figure 3-5).
He was initially managed with ERCP and stenting and was 
started on palliative radiotherapy for bone lesions.  He was planned 
for palliative chemotherapy after recovery of liver function but 
deteriorated further with hepatic encephalopathy.
dI s c u s s I o n
Hepatic carcinosarcoma is an aggressive disease with a mean age 
of onset between 33–75 years[1] and is more common in males. 
Carcinosarcoma is more common in the uterus, ovary, and urinary 
bladder.[2]
The pathogenesis of HCS is controversial. Majority develop in 
non-cirrhotic liver. This findings suggest that HCS develops from a 
stem cell or multipotent hepatic progenitor cell.  The histopathology 
shows both carcinomatous and sarcomatous components with HCC 
being the most common carcinomatous component. In general, 
HCS is an aggressive disease and has a poor prognosis. CT is the 
most common imaging modality used. HCS is a heterogeneous 
tumor with cystic, solid, and necrotic areas. Calcification and 
osteogenesis were observed in 50% of cases especially in those with 
osteosacomatous components. Unlike HCC, HCS rarely exhibits a 
capsule, which might indicate its aggressive behavior.[1] 
The proposed histogenetic mechanisms involved in the 
co-existence of carcinoma and sarcoma components in the same 
tumor include ‘transformation’, ‘combination’ and ‘collision’.[3] 
‘Transformation’ means that, part of the carcinoma undergoes 
sarcomatous transformation. ‘Combination’ signifies that a tumor 
arises from a single stem cell that differentiates into epithelial 
and mesenchymal tissues. ‘Collision’ denotes that carcinoma and 
sarcoma elements of distinct origin invade each other.[3]
There are no characteristic imaging features for HCS. A large 
tumor with more extensive cystic and necrotic degeneration, 
without capsule, with hypervascular enhancement, more frequently 
Figure 5: IHC for SMA
Figure 4: IHC for VIMENTINFigure 3: IHC for PAN CYTOKERATIN
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presented with lymphadenopathy and invasion of adjacent organs, 
these findings may be helpful to distinguish HCS from other 
malignancy.[1] 
Yasutake et al. reported a case of liver carcinosarcoma including 
an HCC-component, which was hyperintense in the hepatobiliary-
phase on gadolinium-ethoxy benzyl  diethylene triaminepentaacetic 
acid (Gd-EOB-DTPA) contrasted enhanced MRI. Further studies are 
required to establish the role of Gd-EOB-DTPA enhanced MRI in 
distinguishing HCS from HCC.[1] 
CT presentation of HCS is nonspecific. Sumiyoshi et al. observed 
that carcinosarcoma on magnetic resonance imaging revealed 
hypointensity on T1-weighted images and heterogeneous 
hyperintensity on T2-weighted images.[4] Shu et al observed that in 
one case of liver carcinosarcoma, triple-phase contrast CT revealed 
a mixed density mass with inhomogeneous enhancement, multiple 
cystic nodules and irregular rim enhancement.[5]
Primary curative resection is the only curative option for 
HCS. Lymphadenopathy is more common with carcinosarcoma, 
and lymphadenectomy improves prognosis in localized hepatic 
carcinosarcoma.[2] In those with the limited disease who undergo 
surgery, the meantime to recurrence was 4.9 months (range: 1 – 
15 months).[2] In one Japanese case report, the recurrences were 
nodal, and repeated surgical excisions managed them. All the nodal 
disease had only sarcomatous elements. In view of the aggressive 
behavior with the dissemination of the sarcomatouselmeents, 
apart from surgery systemic therapy also needs to be considered. 
The optimal chemotherapy program for HCS is still under debate. 
Hepatic carcinosarcoma can undergo dedifferentiation at the 
site of metastases into sarcoma.[6] 
Here, both the patients presented with advanced disease and one 
showed rapid deterioration from the time of symptom onset, giving 
us very little time to intervene.   
co n c lu s I o n
Hepatic carcinosarcoma is a rare, aggressive disease with poor 
outcomes. Carcinosarcoma is a histopathological diagnosis. Further 
studies are required to identify characteristic image findings to 
diagnose carcinosarcoma and to understand the most suitable 
chemotherapy regimen that will produce an adequate response 
and survival benefit.  
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